Work Area: Trade secrets

Latest content

The biggest biopharma patent stories of the year

From President Biden’s backing for a covid IP waiver through a new linkage system in China to big changes in Brazil, it was an action-packed 2021 for the life sciences industries

21 December 2021

The biggest Asia-Pacific IP stories of 2021

Beyond China, there was a lot going on in a market that is home to some of the world’s most important patent-producing businesses

21 December 2021

The 2021 trends that shaped the IP market in five major industries

In-house experts highlight the year’s most important patent developments in auto, life sciences, software, semiconductors and telecoms

20 December 2021

Apple joins Uniloc in opposing court-mandated release of details of the NPE's patent licensing deals

If the CAFC upholds a lower court’s refusal to redact licensees’ identities and information on how much they paid, it could prejudice the interests of both sides in future negotiations, dealmakers say

13 December 2021

Germany’s new government is the last hope for covid IP waiver advocates

A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it

07 December 2021

Vidal looks all set to lead the USPTO after confident Senate hearing

In a strong display, the Biden administration's choice to lead the agency addressed Section 101 reform and Fintiv discretionary denials, but may have left a hostage to fortune on SEP/FRAND

02 December 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

As Micron and UMC settle long-running dispute, all eyes in China are on the US chipmaker’s next move

Taiwan’s UMC will pay an undisclosed sum to end a long, complex and remarkably successful IP enforcement campaign by the Idaho semiconductor firm

29 November 2021

Pfizer acts quickly to tackle alleged covid-19 vaccine trade secrets misappropriation

With strong policies in place to protect confidential information, the company was able to take swift action against an employee after becoming aware of suspicious activity

25 November 2021

Talks over covid vaccine IP waiver appear increasingly futile

Saturday Opinion: The prospect of an international agreement on the proposed suspension of TRIPS now appears vanishingly small

23 October 2021

Unlock unlimited access to all IAM content